“It’s a real luxury situation, unlike usual clinical trials,” study director Peter Kremsner told German Press Agency (DPA) on Friday. “Normally we have trouble coming up with enough test subjects.”

A clinical study began at the university clinic in mid-June to test the tolerability of a vaccine developed by the Tuebingen biopharmaceutical company CureVac.

Since then, around 50 people have received the drug. According to Kremsner, no surprising side effects have occurred yet.

So far everything has been fine, Kremsner said, adding that the study had not revealed any sensational or concerning findings.

Not all of the people who volunteered will be able to take part.

A total of 168 subjects are to be vaccinated in Tuebingen and also in test centers in Hanover and Munich, as well as Ghent, Belgium.

The clinical trial is a so-called phase 1 trial. If it is successful, investigations with significantly more test subjects will follow.

CureVac is working on so-called mRNA vaccines. The mRNA is a kind of messenger molecule that contains the building instructions for the production of proteins. For their vaccine, the Curevac researchers provided mRNA with the building instructions for a protein of the coronavirus SARS-CoV-2.

After vaccination, human cells form this protein, which the body recognizes as foreign. It forms antibodies and other immune cells against it.

Compared to other countries in Europe, Germany has not been as hard hit by the coronavirus. As of Saturday morning, the Robert Koch Institute – the country’s disease authority – reported six more deaths from the day before, bringing the total to 9,060.

Since the beginning of the coronavirus crisis, the country now has a total of 198,556 confirmed cases, after 378 new infections were reported on Saturday.

Source:dailysabah.com